Eli Lilly's Valuation Premium Over Novo Nordisk Widens on Growth Disparity

Eli Lilly (LLY) and Novo Nordisk (NVO), two giants in the lucrative GLP-1 drug market, are trading at starkly different valuations, reflecting a wide gap in investor confidence over their respective growth trajectories. An analysis from Investing.com highlights that while Novo Nordisk appears significantly cheaper on traditional metrics, Eli Lilly commands a substantial premium due to its rapid revenue growth and dominant market share.

A Tale of Two Valuations

The contrast in key financial metrics illustrates the market's current sentiment toward the two pharmaceutical competitors. According to data published on October 1, 2026, the valuation gap is pronounced across several measures.

• Eli Lilly (LLY): Trades with a forward price-to-earnings (P/E) ratio of 31.6x, an EV/EBITDA multiple of 25.6x, and has delivered a 1-year return of +41.1%.
• Novo Nordisk (NVO): Trades at a forward P/E of 11.5x, an EV/EBITDA of 6.9x, and has seen its stock fall by -33.7% over the past year.

Furthermore, Lilly's free cash flow (FCF) yield stands at 1.8%, compared to Novo's much higher 6.9%. This suggests investors are willing to pay a premium for Lilly's growth prospects, while Novo is priced more like a value stock, potentially signaling a value trap to some market observers.

Growth and Market Share Drive the Divide

Ad

The primary driver of this disparity is the significant difference in growth. Lilly's latest reported revenue growth rate was 49.6%, dwarfing Novo Nordisk's 5.6%. On a growth-adjusted basis, Lilly's price/earnings-to-growth (PEG) ratio of 0.41 appears more attractive than Novo's 1.92, according to the analysis.

Market dominance is another key factor. A report dated September 24, 2026, indicated that Lilly holds more than 60% of the GLP-1 market and outsells Novo by a margin of over two to one. Compounding Novo's challenges, an earlier piece from August 5, 2026, flagged a 22% decline in U.S. revenue for its injectable Wegovy and a failed clinical trial for ziltivekimab.

Investor Framework: A Pairs Trade Perspective

This divergence has created a classic "quality versus value" scenario, leading some to analyze it through a pairs trade framework. This is an analytical structure, not a recommendation. One strategy would be to go long on Eli Lilly and short Novo Nordisk, a bet that the performance and valuation gap will continue to widen.

Conversely, a mean-reversion strategy would involve taking a long position in Novo and shorting Lilly, based on the thesis that the valuation gap is unsustainable and will eventually narrow. Investors must weigh significant risks, including the potential for a short squeeze in the heavily sold-off Novo Nordisk. Both companies also face shared industry risks, such as future policy on GLP-1 pricing and Medicare coverage.